Zacks Research Issues Pessimistic Outlook for RDY Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Zacks Research lowered their Q3 2026 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research report issued on Friday, May 30th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.19 for the quarter, down from their prior forecast of $0.20. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ FY2026 earnings at $0.77 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.12 EPS, FY2027 earnings at $0.57 EPS and FY2028 earnings at $0.61 EPS.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Friday, May 9th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. The firm had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%.

Separately, Wall Street Zen raised Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th.

Dr. Reddy’s Laboratories Stock Performance

Shares of Dr. Reddy’s Laboratories stock opened at $14.71 on Monday. Dr. Reddy’s Laboratories has a fifty-two week low of $12.26 and a fifty-two week high of $16.89. The company’s 50 day moving average price is $13.68 and its two-hundred day moving average price is $14.01. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The firm has a market capitalization of $12.28 billion, a P/E ratio of 23.42 and a beta of 0.33.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in Dr. Reddy’s Laboratories in the fourth quarter valued at approximately $145,000. Blue Trust Inc. boosted its stake in Dr. Reddy’s Laboratories by 46.3% during the fourth quarter. Blue Trust Inc. now owns 18,210 shares of the company’s stock worth $288,000 after acquiring an additional 5,763 shares in the last quarter. Caprock Group LLC increased its position in Dr. Reddy’s Laboratories by 280.3% during the 4th quarter. Caprock Group LLC now owns 58,563 shares of the company’s stock valued at $925,000 after buying an additional 43,165 shares in the last quarter. Waldron Private Wealth LLC raised its position in shares of Dr. Reddy’s Laboratories by 476.0% in the 4th quarter. Waldron Private Wealth LLC now owns 17,106 shares of the company’s stock worth $270,000 after purchasing an additional 14,136 shares during the last quarter. Finally, Independence Bank of Kentucky raised its holdings in Dr. Reddy’s Laboratories by 400.0% in the 4th quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after acquiring an additional 2,220 shares during the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.